Fusen Pharmaceutical Co., Ltd.

As of December 31, 2024, Fusen Pharmaceutical Co., Ltd. carries a market capitalization of 598.46M, placing it among publicly traded companies globally. Its enterprise value stands at 982.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, Fusen Pharmaceutical Co., Ltd. has 739.30M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Fusen Pharmaceutical Co., Ltd. maintains a current ratio of 0.59, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, Fusen Pharmaceutical Co., Ltd.'s stock has gained approximately 11.27% over the past 52 weeks. The 50-day moving average sits at 0.92, while the 200-day moving average is 0.99.

As of December 31, 2024, Fusen Pharmaceutical Co., Ltd. holds 22.41M in cash and equivalents against 408.33M in total debt, resulting in a net debt position of 384.80M. Total book value stands at 393.41M, with working capital of -334.65M providing operational flexibility.